Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 3, 2024The Journal of DermatologyOpen Access

Real‐world effectiveness and safety of abrocitinib in 12 Japanese patients with atopic dermatitis and transcriptome analysis with peripheral blood

View Full Paper
Ask AI
Bookmark
Share

Authors

AUAkihiko UchiyamaKKKeiji KosakaMIMai Ishikawa

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Uchiyama et al. (2024) studied this question.

synapsesocial.com/papers/68e75ef0b6db6435876d58aahttps://doi.org/10.1111/1346-8138.17173
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abrocitinib: 1‐Year Real‐Life Experience From the French OMCCI Registry2026
  2. 2Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)2026
  3. 3Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24‐week multicenter study2024 · 15 citations
  4. 4Effectiveness of Abrocitinib in Cyclosporine-Resistant Atopic Dermatitis: A Real-world Experience from the Indian Subcontinent2026
  5. 5Efficacy of abrocitinib in patients with atopic dermatitis resistant to Janus kinase inhibitors2026